drug
rifaximin
Marketedupdated 5mo agoby Salix Pharmaceuticals Ltd
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2all catalysts(0)
nothing on the calendar yet
Trials studying rifaximin
- phase4Rifaximin for the Secondary Prevention of Recurrent Pouchitis
- phase2Rifaximin SSD in Dementia Trial
- phase4Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea
- phase3Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis
- phase2Microbiota Intervention to Change the Response of Parkinson's Disease
- phase3Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis
- phase3Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites
- phase4Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 2, 2027
332 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (24)
- Oct 2, 2029method-of-use (U-1481)US 86425733.0y
- Oct 2, 2029method-of-use (U-1481)US 89693983.0y
- Jul 24, 2029method-of-use (U-1481)US 103148282.8y
- Jul 24, 2029method-of-use (U-2579)US 103353972.8y
- Jul 24, 2029method-of-use (U-2579)US 107096942.8y
- Jul 24, 2029method-of-use (U-1121)US 79281152.8y
- Jul 24, 2029method-of-use (U-1562)US 88290172.8y
- Jul 24, 2029method-of-use (U-1481)US 89462522.8y
- Jul 24, 2029method-of-use (U-1481)US 94211952.8y
- Jul 24, 2029method-of-use (U-1994)US 96298282.8y
- Feb 26, 2029method-of-use (U-2644)US 104563842.4y
- Feb 26, 2029method-of-use (U-2643)US 107656672.4y
- Feb 26, 2029method-of-use (U-3512)US 115649122.4y
- Feb 26, 2029method-of-use (U-3706)US 117795712.4y
- Sep 2, 2027compositionUS 8193196332d
- Sep 2, 2027compositionUS 8193196332d
- Feb 27, 2026method-of-use (U-1708)US 10703763
- Feb 27, 2026method-of-use (U-2848)US 10703763
- Feb 27, 2026formulationUS 8518949
- Feb 27, 2026formulationUS 8518949
- Feb 27, 2026compositionUS 8741904
- Feb 27, 2026compositionUS 8741904
- Feb 27, 2026formulationUS 9271968
- Feb 27, 2026formulationUS 9271968
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that